SCHEMBL85812

SCHEMBL85812

NC(=O)/C(=C1\Nc2ccc(CCN3CCC(F)(F)CC3)cc2S1)c1nccc(C(F)(F)F)n1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 1/20 0.33
ABCC1 P33527 3/20 0.32
CYP3A4 P08684 2/20 0.32
HRH3 Q9Y5N1 1/20 0.32
IKBKE Q14164 1/20 0.32
TBK1 Q9UHD2 1/20 0.32
GRM2 Q14416 3/20 0.32
HTR1A P08908 4/20 0.31
PRCP P42785 2/20 0.31
DRD2 P14416 1/20 0.31
DRD4 P21917 1/20 0.31
KCNH2 Q12809 1/20 0.31
PRMT5 O14744 1/20 0.31
WDR77 Q9BQA1 1/20 0.31
OPRM1 P35372 1/20 0.30
SIGMAR1 Q99720 1/20 0.30
ACKR3 P25106 2/20 0.30
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30
SLC6A3 Q01959 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL86069 0.91 ABCC1 (0.34) ABCC1CYP3A4HRH3IKBKETBK1
SCHEMBL78085 0.90 CYP3A4 (0.38) ABCC1CYP3A4HRH3OPRM1SIGMAR1
SCHEMBL85807 0.90 CYP3A4 (0.38) ABCC1CYP3A4HRH3OPRM1SIGMAR1
SCHEMBL77158 0.90 FGFR1 (0.34) ABCC1CYP3A4HRH3IKBKETBK1
SCHEMBL86057 0.90 FGFR1 (0.34) ABCC1CYP3A4HRH3IKBKETBK1
SCHEMBL86474 0.84 TBK1 (0.43) IKBKETBK1GRM2KCNH2ACKR3
SCHEMBL86055 0.83 HMOX1 (0.36) CYP3A4
SCHEMBL77685 0.83 HMOX1 (0.36) CYP3A4
SCHEMBL86060 0.83 ICAM1 (0.37) IKBKETBK1GRM2
SCHEMBL86100 0.82 SYK (0.40) IKBKETBK1GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129396-B2 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors TELIK, INC. (US) 2012-03-06 US disclosed
US-8129396-B2 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors TELIK, INC. (US) 2012-03-06 US disclosed
US-20100081653-A1 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors TELIK, INC. 2010-04-01 US disclosed
US-20100081653-A1 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors TELIK, INC. 2010-04-01 US disclosed
WO-2010036873-A1 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors TELIK, INC. (US) 2010-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081653-A1 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors MAP3K2, MAP4K2, MAP3K12 SCN10A 3068/4885ABCC1 2402/4885CYP3A4 4232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.